Eli Lilly Earnings Surge 56% as Stock Soars 8.3%
Can Eli Lilly’s explosive GLP-1 demand and raised outlook really justify one of the richest valuations in global pharma? Maik Kemper Editor in Chief “What we’re seeing now…
Eli Lilly Acquisition Boom: $2.3B Ajax Oncology Shock
Is the latest Eli Lilly Acquisition of Ajax Therapeutics a smart oncology pivot or a risky $2.3 billion side bet? Maik Kemper Editor in Chief Conclusion Overall, the…
Eli Lilly Acquisition Boom: Multi‑Billion Cancer and Obesity Bet
Can the latest Eli Lilly Acquisition in next‑gen cancer therapy really justify its sky‑high valuation beyond the obesity drug boom? Maik Kemper Editor in Chief Kelonia’s in‑vivo CAR‑T…
Eli Lilly GLP-1 pill Foundayo: Can the Boom Last?
Can the new Eli Lilly GLP-1 pill Foundayo justify the stock’s rich valuation and extend its obesity drug dominance? Maik Kemper Editor in Chief Conclusion Overall, the Eli…
Eli Lilly Weight Loss Drugs Boom: Can Foundayo Defend Margins?
Can Eli Lilly’s new Foundayo pill and GLP‑1 pipeline keep its obesity lead as a brutal price war erupts? Maik Kemper Editor in Chief Conclusion Overall, the expanding…
Eli Lilly Weight-Loss Strategy vs Novo: Price War Shock
Can the Eli Lilly Weight-Loss Strategy stay on top as Novo Nordisk slashes prices and AI reshapes the obesity drug race? Maik Kemper Editor in Chief Conclusion In…
Eli Lilly Foundayo Soars +4.6% as GLP-1 Pill Bets Grow
Can Eli Lilly Foundayo and the Centessa deal push Lilly’s GLP-1 dominance into an even more powerful multi-drug growth story? Maik Kemper Editor in Chief As a convenient,…
Eli Lilly GLP-1 Strategy Boom and Revenue Shock
Can Eli Lilly’s GLP-1 boom keep powering the stock as regulation, lawsuits and ETF concentration risks close in? Maik Kemper Editor in Chief Conclusion The Eli Lilly GLP-1…
Eli Lilly Retatrutide Boom: Triple-Agonist Trial Shock
Can Eli Lilly Retatrutide’s powerful Phase 3 diabetes data reignite confidence in the GLP-1 boom despite rising competitive and pricing fears? Maik Kemper Editor in Chief With triple…
Eli Lilly Forecast Warning after HSBC’s bearish reset
Is the latest bearish Eli Lilly Forecast a rare buying opportunity or the start of a painful valuation reset in GLP-1 leaders? Maik Kemper Editor in Chief The…